Antonio S. Montecalvo - Mar 9, 2022 Form 4 Insider Report for Organogenesis Holdings Inc. (ORGO)

Role
Vice President, Health Policy
Signature
/s/ William R. Kolb, Attorney-in-Fact
Stock symbol
ORGO
Transactions as of
Mar 9, 2022
Transactions value $
-$665,664
Form type
4
Date filed
3/11/2022, 05:42 PM
Previous filing
Feb 17, 2022
Next filing
Apr 5, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ORGO Class A Common Stock Sale -$85.2K -10K -12.02% $8.52 73.2K Mar 9, 2022 Direct F1
transaction ORGO Class A Common Stock Options Exercise $160K +46.1K +62.96% $3.46 119K Mar 10, 2022 Direct
transaction ORGO Class A Common Stock Options Exercise $77.5K +22.4K +18.77% $3.46 142K Mar 10, 2022 Direct
transaction ORGO Class A Common Stock Sale -$817K -97.4K -68.75% $8.39 44.3K Mar 10, 2022 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ORGO Stock Option (Right to Buy) Options Exercise $0 -46.1K -45.42% $0.00 55.4K Mar 10, 2022 Class A Common Stock 46.1K $3.46 Direct F3
transaction ORGO Stock Option (Right to Buy) Options Exercise $0 -22.4K -22.27% $0.00 78.2K Mar 10, 2022 Class A Common Stock 22.4K $3.46 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $8.50 to $8.54, inclusive. The reporting person undertakes to provide to Organogenesis, any security holder of Organogenesis, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1) to this Form 4.
F2 The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $8.34 to $8.42, inclusive. The reporting person undertakes to provide to Organogenesis, any security holder of Organogenesis, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4.
F3 The shares underlying the option vested or shall vest 20% annually beginning on January 1, 2018.
F4 The shares underlying the option vested or shall vest 20% annually beginning on December 31, 2017.